We found that P2Et plus αPD-L1 treatment induced a higher cytotoxic potential of cytotoxic cells both in melanoma and in the breast cancer model (Figures 6C, D), suggesting that combined therapy improves CD8+ T cell effector functions, which would entail a better response to immunotherapy. Here, CD8A is linked to breast carcinoma.